The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.
This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.
Ionis Pharmaceuticals (IONS) is the sponsoring company for this trial. BiotechSign currently grades this company C (55/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.